“…[4] Moreover, increasing the number of HCEnCs through their expansion in eye bank corneas would be beneficial to reduce tissue wastage, [5] as the high cell death rate during storage, in particular following apoptosis in the corneal endothelium, leads to a decrease in HCEnCs density [5] and rejection of more than 35% of stored corneas. [2,6] A deeper understanding and modulation of the molecular mechanisms regulating HCEnCs proliferation is fundamental to increase their density; [7,8] gene therapy has been explored for this purpose in many ways, including by inhibiting apoptosis through overexpression of antiapoptotic genes (e.g., Bcl-xl), [9,10] by inducing cell proliferation through overexpression of transcription factors such (e.g., E2F2), [11] or by downregulation of cell cycle inhibitors (e.g., p21, p16, [12,13] p27, [14] SNAI1, and CDK2). [15] Yet, nucleotide delivery to the corneal endothelium is challenging, as the cells are postmitotic and thus hard to transfect.…”